Please login to the form below

bipolar disorder

This page shows the latest bipolar disorder news and features for those working in and with pharma, biotech and healthcare.

Sanofi faces manslaughter allegations in France over Depakine deaths

Depakine has been marketed by Sanofi since 1967 as an anti-epileptic and bipolar disorder treatment, and has since been associated with foetus malformation and neurodevelopmental disorders including autism and spina

Latest news

Botox strength bolsters Allergan ahead of AbbVie takeover

The dopamine D2, D3 receptor partial agonist for schizophrenia and bipolar disorder could top the $1bn blockbuster threshold, well ahead of analyst forecast of around half that amount at peak just ... A new approval in bipolar depression has contributed
Sanofi indicted in France over epilepsy drug birth defects

Despite its maturity, the drug has been one of Sanofi’s reliable mid-size products, bringing in around 450m in sales from use in epilepsy and bipolar disorder in 2018.
Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug. The FDA has started its review of Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder – ALKS 3831 – setting up a ... Olanzapine is an effective and well
AstraZeneca divests Seroquel rights to focus on key therapy areas

Second divestment to Germany-based Cheplapharm this year. AstraZeneca has sold the commercial rights to schizophrenia and bipolar disorder drugs Seroquel and Seroquel XR to Cheplapharm. .
Sage raises $575m ahead of FDA review date for Zulresso

It also has an FDA breakthrough designation for this indication. The follow-up is also being developed in a phase 3 programme as a short oral course for major depressive disorder, ... It is also in earlier-stage studies for MDD plus insomnia as a

More from news
Approximately 7 fully matching, plus 86 partially matching documents found.

Latest Intelligence

Drug pricing in Ireland

As such, patients with coronary syndromes, multiple sclerosis, bipolar disorder and Hepatitis C were being denied access to effective treatments, while treatments for other diseases were also subject to restrictions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

AN ADVOCACY Rx FOR PROGRESS IN MENTAL HEALTH

there’s an abundance of smart thinking on how to improve the lives of people who struggle with major depression, schizophrenia, bipolar disorder, and other serious conditions.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...